{{Use dmy dates|date=March 2014}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458780865
| IUPAC_name = (3''R'')-''N''-Methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
| image = Atomoxetine structure.svg
| width = 220
| image2 = Atomoxetine ball-and-stick model.png
| width2 = 240
<!--Clinical data-->
| tradename = Strattera, others
| Drugs.com = {{drugs.com|monograph|atomoxetine-hydrochloride}}
| MedlinePlus = a603013
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]
<!--Pharmacokinetic data-->
| bioavailability = 63 to 94%<ref name = MSR>{{cite web|title=atomoxetine (Rx) – Strattera|work=Medscape Reference|publisher=WebMD|accessdate=10 November 2013|url=http://reference.medscape.com/drug/strattera-atomoxetine-342994}}</ref><ref name = TGA /><ref name = DM>{{cite web|title=ATOMOXETINE HYDROCHLORIDE capsule [Mylan Pharmaceuticals Inc.]|work=DailyMed|publisher=Mylan Pharmaceuticals Inc.|date=October 2011|accessdate=10 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bdab7205-d0ff-41c3-8430-2d399dfaa759}}</ref>
| protein_bound = 98%<ref name = MSR /><ref name = TGA /><ref name = DM />
| metabolism = [[Hepatic]], via [[CYP2D6]]<ref name = MSR /><ref name = TGA /><ref name = DM />
| elimination_half-life = 4.5-19 hours<ref name = MSR /><ref name = TGA /><ref name = DM /><ref name = PMID15910008/><ref name = PMID26314574/>
| excretion = [[Kidney|Renal]] (80%) and faecal (17%)<ref name = MSR /><ref name = TGA /><ref name = DM />
<!--Identifiers-->
| IUPHAR_ligand = 7118
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 83015-26-3
| ATC_prefix = N06
| ATC_suffix = BA09
| PubChem = 54841
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00289
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 49516
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ASW034S0B8
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07473
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 127342
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 641
| synonyms = (''R'')-''N''-Methyl-3-phenyl-3-(''o''-tolyloxy)propan-1-amine
<!--Chemical data-->
| C=17 | H=21 | N=1 | O=1
| molecular_weight = 255.36 g/mol<br/>291.81 g/mol (hydrochloride)
| SMILES = CC1=C(C=CC=C1)O[C@H](CCNC)C2=CC=CC=C2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VHGCDTVCOLNTBX-QGZVFWFLSA-N
}}

'''Atomoxetine''', sold under the brand name '''Strattera''' among others, is a [[norepinephrine reuptake inhibitor|norepinephrine (noradrenaline) reuptake inhibitor]] which is approved for the treatment of [[attention deficit hyperactivity disorder]] (ADHD).<ref name="PI">{{cite web|title=STRATTERA<sup>®</sup> (atomoxetine hydrochloride) CAPSULES for Oral Use. Full Prescribing Information|publisher=[[Eli Lilly and Company]]|date=20 February 2014|url=http://pi.lilly.com/us/strattera-pi.pdf|format=PDF|location=[[Indianapolis]], [[United States of America|USA]]|accessdate=23 May 2014}}</ref> As of 2017, it is available as a [[generic medication]] in the [[United States]].<ref>{{cite web|title=Press Announcements - FDA approves first generic Strattera for the treatment of ADHD|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm561096.htm|website=www.fda.gov|accessdate=2 June 2017|language=en}}</ref>

{{TOC limit|3}}

==Medical uses==

===Attention deficit hyperactivity disorder===
Atomoxetine is approved for use in children, adolescents, and adults.<ref name="PI" /> However, its efficacy has not been studied in children under six years old.<ref name = TGA>{{cite web|title=STRATTERA® (atomoxetine hydrochloride)|work=TGA eBusiness Services|publisher=Eli Lilly Australia Pty. Limited|date=21 August 2013|accessdate=10 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04269-3}}</ref> Its primary advantage over the standard [[psychostimulant|stimulant]] treatments for ADHD is that it has little known abuse potential.<ref name = TGA /> While it has been shown to significantly reduce [[ADHD-I|inattentive]] and [[ADHD-H|hyperactive]] symptoms, the responses were lower than the response to stimulants. Additionally, 40% of participants who were treated with atomoxetine experienced significant residual ADHD symptoms.<ref>{{Cite journal|last=Ghuman|first=Jaswinder K.|last2=Hutchison|first2=Shari L.|date=2014-11-01|title=Atomoxetine is a second-line medication treatment option for ADHD|url=http://ebmh.bmj.com/content/17/4/108|journal=Evidence Based Mental Health|language=en|volume=17|issue=4|pages=108–108|doi=10.1136/eb-2014-101805|issn=1468-960X|pmid=25165169}}</ref>

The initial therapeutic effects of atomoxetine usually take 2–4 weeks to become apparent.<ref name = MSR /> A further 2–4 weeks may be required for the full therapeutic effects to be seen.<ref name="Maudsley">{{cite book | isbn = 978-0-470-97948-8 | title = The Maudsley prescribing guidelines in psychiatry | last1 = Taylor | first1 = D |author2=Paton, C |author3=Shitij, K | year = 2012 | publisher = Wiley-Blackwell | location = West Sussex  | pages =  }}</ref> Its efficacy may be less than that of stimulant medications.<ref>{{cite book|title=Adult ADHD Diagnostic Assessment and Treatment|isbn=978-1-4471-4137-2|doi=10.1007/978-1-4471-4138-9|author=Kooij, JJS|year=2013|url=https://link.springer.com/content/pdf/10.1007%2F978-1-4471-4138-9|format=PDF|publisher=Springer London}}</ref>

Unlike [[Alpha-adrenergic agonist|α<sub>2</sub> adrenoceptor agonists]] such as [[guanfacine]] and [[clonidine]], atomoxetine's use can be abruptly stopped without significant discontinuation effects being seen.<ref name = TGA />

==Contraindications==
Contraindications include:<ref name = TGA />

{{colbegin}}
* Hypersensitivity to atomoxetine or any of the excipients in the product
* Symptomatic cardiovascular disease including:
:-moderate to severe [[hypertension]]
:-[[atrial fibrillation]]
:-[[atrial flutter]]
:-[[ventricular tachycardia]]
:-[[ventricular fibrillation]]
:-[[ventricular flutter]]
:-advanced [[arteriosclerosis]]
* Severe cardiovascular disorders
* [[Pheochromocytoma]]
* Concomitant treatment with [[monoamine oxidase inhibitors]]
* Narrow angle [[glaucoma]]
* Poor metabolizers (due to the metabolism of atomoxetine by [[CYP2D6]])
{{colend}}

== Adverse effects ==
'''<big>Incidence of adverse effects:</big>'''<ref name = TGA /><ref name = DM /><ref name = EMC>{{cite web|title=Strattera 10mg, 18mg, 25mg, 40mg, 60mg, 80mg or 100mg hard capsules|work=electronic Medicines Compendium|date=28 May 2013|accessdate=10 November 2013|url=http://www.medicines.org.uk/emc/medicine/14482/SPC/Strattera+10mg%2c+18mg%2c+25mg%2c+40mg%2c+60mg%2c+80mg+or+100mg+hard+capsules}}</ref><ref>{{cite web|title=Strattera Product Insert|accessdate=8 December 2013|url=http://medlibrary.org/lib/rx/meds/strattera-5/page/4/}}</ref>

'''Very common (>10% incidence) adverse effects include:'''
* Nausea (26%)
* [[Xerostomia]] (Dry mouth) (20%)
* Appetite loss (16%)
* Insomnia (15%)
* Fatigue (10%)
* Headache
* Cough

'''Common (1-10% incidence) adverse effects include:'''

{{colbegin}}
* Constipation (8%)
* Dizziness (8%)
* Erectile dysfunction (8%)
* [[Somnolence]] (sleepiness) (8%)
* Abdominal pain (7%)
* Urinary hesitation (6%)
* Tachycardia (high heart rate) (5-10%)
* Hypertension (high blood pressure) (5-10%)
* Irritability (5%)
* Abnormal dreams (4%)
* [[Dyspepsia]] (4%)
* Ejaculation disorder (4%)
* [[Hyperhidrosis]] (abnormally increased sweating) (4%)
* Vomiting (4%)
* Hot flashes (3%)
* [[Paraesthesia]] (sensation of tingling, tickling, etc.) (3%)
* Menstrual disorder (3%)
* Weight loss (2%)
* [[Depression (mood)|Depression]]
* [[Sinus headache]]
* [[Dermatitis]]
* [[Mood swing]]s
{{colend}}

'''Uncommon (0.1-1% incidence) adverse effects include:'''

{{colbegin}}
* Suicide-related events
* Hostility
* [[Pseudobulbar affect|Emotional lability]]
* Aggression
* [[Psychosis]]
* [[Syncope (medicine)|Syncope]] (fainting)
* Tremor
* [[Migraine]]
* [[Hypoaesthesia]]
* Seizure
* [[Palpitations]]
* [[Sinus tachycardia]]
* [[QT interval]] prolongation
* Increased blood [[bilirubin]]
* Allergic reactions
{{colend}}

'''Rare (0.01-0.1% incidence) adverse effects including:'''

* [[Raynaud's phenomenon]]
* Abnormal/increased liver function tests
* [[Jaundice]]
* [[Hepatitis]]
* Liver injury
* Acute [[liver failure]]
* [[Urinary retention]]
* [[Priapism]]<ref name=FDA>{{cite web|url=http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089138.pdf|title=STRATTERA Medication Guide|work=[[Eli Lilly and Company]]|year=2003|accessdate=17 December 2013}}</ref>
* Male genital pain

The [[Food and Drug Administration|FDA]] of the [[United States of America|US]] has issued a [[black box warning]] for suicidal behaviour/ideation.<ref name = DM /> Similar warnings have been issued in Australia.<ref name = TGA /><ref>{{cite news|title=Atomoxetine and suicidality in children and adolescents |newspaper=Australian Prescriber |volume=36 |issue=5 |page=166 |date=October 2013 |accessdate=10 November 2013 |url=http://www.australianprescriber.com/magazine/36/5/166/9 |deadurl=yes |archiveurl=https://web.archive.org/web/20131110153948/http://www.australianprescriber.com/magazine/36/5/166/9 |archivedate=10 November 2013 |df=dmy }}</ref> Unlike stimulant medications, atomoxetine does not have abuse liability or the potential to cause withdrawal effects on abrupt discontinuation.<ref name = TGA />

==Overdose==
Atomoxetine is relatively non-toxic in overdose. Single-drug overdoses involving over 1500&nbsp;mg of atomoxetine have not resulted in death.<ref name = TGA /> The most common symptoms of overdose include:<ref name = TGA />

{{colbegin}}
* Gastrointestinal symptoms
* Somnolence
* Dizziness
* Tremor
* Abnormal behaviour
* Hyperactivity
* Agitation
* Dry mouth
* Tachycardia
* Hypertension
* Mydriasis
{{colend}}

Less common symptoms:<ref name = TGA />
* Seizures
* [[QT interval|QTc interval]] prolongation

The recommended treatment for atomoxetine overdose includes use of [[Activated carbon|activated charcoal]] to prevent further absorption of the drug.<ref name = TGA />

==Interactions==
Atomoxetine is a [[substrate (biochemistry)|substrate]] for [[CYP2D6]]. Concurrent treatment with a CYP2D6 inhibitor such as [[bupropion]], [[fluoxetine]], or [[paroxetine]] has been shown to increase plasma atomoxetine by 100% or more, as well as increase ''N''-desmethylatomoxetine levels and decrease plasma 4-hydroxyatomoxetine levels by a similar degree.<ref name = PMID27518170>{{cite journal|last1=Todor|first1=I|last2=Popa|first2=A|last3=Neag|first3=M|last4=Muntean|first4=D|last5=Bocsan|first5=C|last6=Buzoianu|first6=A|last7=Vlase|first7=L|last8=Gheldiu|first8=AM|last9=Briciu|first9=C|title=Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers.|journal=Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques|date=NaN|volume=19|issue=2|pages=198–207|pmid=27518170}}</ref><ref name = PMID21765848>{{cite journal|last1=Kasi|first1=PM|last2=Mounzer|first2=R|last3=Gleeson|first3=GH|title=Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system.|journal=Case reports in medicine|date=2011|volume=2011|pages=952584|doi=10.1155/2011/952584|pmid=21765848}}</ref><ref name = PMID12412820>{{cite journal|last1=Belle|first1=DJ|last2=Ernest|first2=CS|last3=Sauer|first3=JM|last4=Smith|first4=BP|last5=Thomasson|first5=HR|last6=Witcher|first6=JW|title=Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.|journal=Journal of clinical pharmacology|date=November 2002|volume=42|issue=11|pages=1219–27|pmid=12412820}}</ref>

Atomoxetine has been found to directly inhibit [[hERG]] potassium currents with an [[IC50|IC<sub>50</sub>]] of 6.3 μM, which has the potential to cause [[arrhythmia]].<ref name = PMID21765848/><ref name = PMID19154426>{{cite journal|last1=Scherer|first1=D|last2=Hassel|first2=D|last3=Bloehs|first3=R|last4=Zitron|first4=E|last5=von Löwenstern|first5=K|last6=Seyler|first6=C|last7=Thomas|first7=D|last8=Konrad|first8=F|last9=Bürgers|first9=HF|last10=Seemann|first10=G|last11=Rottbauer|first11=W|last12=Katus|first12=HA|last13=Karle|first13=CA|last14=Scholz|first14=EP|title=Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents.|journal=British journal of pharmacology|date=January 2009|volume=156|issue=2|pages=226–36|doi=10.1111/j.1476-5381.2008.00018.x|pmid=19154426}}</ref> [[QT prolongation]] has been reported with atomoxetine at therapeutic doses and in overdose; it is suggested that atomoxetine not be used with other [[Drug-induced QT prolongation|medications that may prolong the QT interval]], concomitantly with CYP2D6 inhibitors, and caution to be used in poor metabolizers.<ref name = PMID21765848/>

Other notable drug interactions include:<ref name =TGA />

* [[Antihypertensive]] agents, due to atomoxetine acting as an indirect sympathomimetic
* Indirect-acting [[sympathomimetic]]s, such as [[pseudoephedrine]], [[norepinephrine reuptake inhibitors]], or [[Monoamine oxidase inhibitor|MAOIs]]
* Direct-acting sympathomimetics, such as [[phenylephrine]] or other [[Alpha-1 adrenergic receptor#Ligands|α<sub>1</sub> adrenoceptor agonists]], including [[pressor]]s such as [[dobutamine]] or [[isoprenaline]] and [[Beta2-adrenergic agonist|β<sub>2</sub> adrenoceptor agonists]]
* Highly plasma protein-bound drugs: atomoxetine has the potential to displace these drugs from plasma proteins which may potentiate their adverse or toxic effects. ''In vitro'', atomoxetine does not affect the plasma protein binding of [[aspirin]], [[desipramine]], [[diazepam]], [[paroxetine]], [[phenytoin]], or [[warfarin]]<ref name = PMID15910008/><ref name = part2>{{cite web|title=21-411 Strattera Clinical Pharmacology Biopharmaceutics Review Part 2|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera_biopharmr_P2.pdf}}</ref>

==Pharmacology==

===Pharmacodynamics===
{| class="wikitable floatright" style="font-size:small;"
|+'''Atomoxetine (and metabolites)'''<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=atomoxetine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! {{abbr|ATX|Atomoxetine}} !! {{abbr|4-OH-ATX|4-Hydroxyatomoxetine}} !! {{abbr|N-DM-ATX|''N''-Desmethylatomoxetine}}
|-
| '''{{abbrlink|SERT|Serotonin transporter}}''' || '''77''' || '''43''' || '''{{abbr|ND|No data}}'''
|-
| '''{{abbrlink|NET|Norepinephrine transporter}}''' || '''5''' || '''3''' || '''92'''
|-
| [[Dopamine transporter|DAT]] || 1,451 || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || >1,000 || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT1B receptor|5-HT<sub>1B</sub>]] || >1,000 || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT1D receptor|5-HT<sub>1D</sub>]] || >1,000 || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT2 receptor|5-HT<sub>2</sub>]] || 2,000 || 1,000 || 1,700
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || >1,000 || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || >1,000 || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[Alpha-1 adrenergic receptor|α<sub>1</sub>]] || 11,400 || 20,000 || 19,600
|-
| [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] || 29,800 || >30,000 || >10,000
|-
| [[Beta-1 adrenergic receptor|β<sub>1</sub>]] || 18,000 || 56,100 || 32,100
|-
| [[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]] || >100,000 || >100,000 || >100,000
|-
| [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]] || >100,000 || >100,000 || >100,000
|-
| [[Dopamine receptor D1|D<sub>1</sub>]] || >10,000 || >10,000 || >10,000
|-
| [[Dopamine receptor D2|D<sub>2</sub>]] || >10,000 || >10,000 || >10,000
|-
| [[Histamine receptor|H<sub>1</sub>]] || 12,100 || >100,000 || >100,000
|-
| '''{{abbrlink|MOR|μ-Opioid receptor}}''' || {{abbr|ND|No data}} || '''422''' || {{abbr|ND|No data}}
|-
| '''{{abbrlink|DOR|δ-Opioid receptor}}''' || {{abbr|ND|No data}} || '''300''' || {{abbr|ND|No data}}
|-
| '''{{abbrlink|KOR|κ-Opioid receptor}}''' || {{abbr|ND|No data}} || '''95''' || {{abbr|ND|No data}}
|-
| [[Sigma-1 receptor|σ<sub>1</sub>]] || >1,000 || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[GABAA receptor|GABA<sub>A</sub>]]''' || '''200''' || >30,000 || >10,000
|-
| [[NMDA receptor|NMDA]] || 3,470<sup>a</sup> || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[G protein-coupled inwardly-rectifying potassium channel|K<sub>ir</sub>3.1/3.2]] || 10,900<sup>b</sup> || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[G protein-coupled inwardly-rectifying potassium channel|K<sub>ir</sub>3.2]] || 12,400<sup>b</sup> || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[G protein-coupled inwardly-rectifying potassium channel|K<sub>ir</sub>3.1/3.4]] || 6,500<sup>b</sup> || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| [[hERG]] || 6,300 || 20,000 || 5,710
|- class="sortbottom"
| colspan="5" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site. All values are for human receptors unless otherwise specified. <sup>a</sup>rat cortex. <sup>b</sup>''Xenopus'' oocytes. Additional sources:<ref name = NPP2002 /><ref name="PMID15225731" /><ref>{{cite journal|last=Bymaster|first=FP|author2=Katner, JS|author3=Nelson, DL|author4=Hemrick-Luecke, SK|author5=Threlkeld, PG|author6=Heiligenstein, JH|author7=Morin, SM|author8=Gehlert, DR|author9= Perry, KW|title=Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder|journal=Neuropsychopharmacology|date=November 2002|volume=27|issue=5|pages=699–711|pmid=12431845|doi=10.1016/S0893-133X(02)00346-9}}</ref><ref name = PMID15910008/><ref name = part2 />
|}

Atomoxetine inhibits the presynaptic [[norepinephrine transporter]] (NET), preventing the reuptake of norepinephrine throughout the brain along with inhibiting the reuptake of dopamine in specific brain regions such as the prefrontal cortex, where [[dopamine transporter]] (DAT) expression is minimal.<ref name = PMID15910008/> In rats, atomoxetine increased [[prefrontal cortex]] [[catecholamine]] concentrations without altering [[dopamine]] levels in the [[striatum]] or [[nucleus accumbens]]; in contrast, [[methylphenidate]], a [[dopamine reuptake inhibitor]], was found to increase prefrontal, striatal, and accumbal dopamine levels to the same degree.<ref name = NPP2002>{{cite journal|title=Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder|journal=Neuropsychopharmacology|date=November 2002|volume=27|issue=5|pages=699–711|doi=10.1016/S0893-133X(02)00346-9|pmid=12431845|author1=Bymaster, FP |author2=Katner, JS |author3=Nelson, DL |author4=Hemrick-Luecke, SK |author5=Threlkeld, PG |author6=Heiligenstein, JH |author7=Morin, SM |author8=Gehlert, DR |author9=Perry, KW |url=http://www.nature.com/npp/journal/v27/n5/pdf/1395936a.pdf|format=PDF}}</ref> In mice, atomoxetine was also found to increase prefrontal catecholamine levels without affecting striatal or accumbal levels.<ref name = PMID20403082>{{cite journal|last1=Koda|first1=K|last2=Ago|first2=Y|last3=Cong|first3=Y|last4=Kita|first4=Y|last5=Takuma|first5=K|last6=Matsuda|first6=T|title=Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice.|journal=Journal of neurochemistry|date=July 2010|volume=114|issue=1|pages=259–70|doi=10.1111/j.1471-4159.2010.06750.x|pmid=20403082}}</ref>

Atomoxetine's status as a [[serotonin transporter]] (SERT) inhibitor at clinical doses in humans is uncertain. A [[Positron emission tomography|PET imaging]] study on [[rhesus monkey]]s found that atomoxetine occupied >90% and >85% of neural NET and SERT, respectively.<ref name="DingNaganawa2014">{{cite journal|last1=Ding|first1=Y.-S.|last2=Naganawa|first2=M.|last3=Gallezot|first3=J.-D.|last4=Nabulsi|first4=N.|last5=Lin|first5=S.-F.|last6=Ropchan|first6=J.|last7=Weinzimmer|first7=D.|last8=McCarthy|first8=T.J.|last9=Carson|first9=R.E.|last10=Huang|first10=Y.|last11=Laruelle|first11=M.|title=Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD|journal=NeuroImage|volume=86|year=2014|pages=164–171|issn=1053-8119|doi=10.1016/j.neuroimage.2013.08.001|pmid=23933039|quote=The noradrenergic action also exerts an important clinical effect in different antidepressant classes such as desipramine and nortriptyline (tricyclics, prevalent noradrenergic effect), reboxetine and atomoxetine (relatively pure noradrenergic reuptake inhibitor (NRIs)), and dual action antidepressants such as the serotonin noradrenaline reuptake inhibitors (SNRIs), the noradrenergic and dopaminergic reuptake inhibitor (NDRI) bupropion, and other compounds (e.g., mianserin, mirtazapine), which enhance the noradrenergic transmission}}</ref> However, both mouse and rat microdialysis studies have failed to find an increase in extracellular [[serotonin]] in the prefrontal cortex following acute or chronic atomoxetine treatment.<ref name = NPP2002/><ref name = PMID20403082/> Supporting atomoxetine's selectivity, a human study found no effects on platelet serotonin uptake (a marker of SERT inhibition) and inhibition of the [[Antihypotensive agent|pressor]] effects of [[tyramine]] (a marker of NET inhibition).<ref>{{cite journal|last1=Zerbe|first1=RL|last2=Rowe|first2=H|last3=Enas|first3=GG|last4=Wong|first4=D|last5=Farid|first5=N|last6=Lemberger|first6=L|title=Clinical pharmacology of tomoxetine, a potential antidepressant.|journal=The Journal of pharmacology and experimental therapeutics|date=January 1985|volume=232|issue=1|pages=139–43|pmid=3965689}}</ref>

Atomoxetine has been found to act as an [[NMDA receptor antagonist]] in rat cortical neurons at therapeutic concentrations.<ref name = PMID20423340>{{cite journal|title=Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations|journal=British Journal of Pharmacology|date=May 2010|volume=160|issue=2|pages=283–291|pmid=20423340|doi=10.1111/j.1476-5381.2010.00707.x|pmc=2874851|author1=Ludolph, AG |author2=Udvardi, PT |author3=Schaz, U |author4=Henes, C |author5=Adolph, O |author6=Weigt, HU |author7=Fegert, JM |author8=Boeckers, TM |author9=Föhr, KJ }}</ref><ref name = PMID28167075>{{cite journal|last1=Barygin|first1=OI|last2=Nagaeva|first2=EI|last3=Tikhonov|first3=DB|last4=Belinskaya|first4=DA|last5=Vanchakova|first5=NP|last6=Shestakova|first6=NN|title=Inhibition of the NMDA and AMPA receptor channels by antidepressants and antipsychotics.|journal=Brain research|date=1 April 2017|volume=1660|pages=58–66|doi=10.1016/j.brainres.2017.01.028|pmid=28167075}}</ref> It causes a use-dependent open-channel block and its binding site overlaps with the Mg<sup>2+</sup> binding site.<ref name = PMID20423340/><ref name = PMID28167075/> Atomoxetine's ability to increase prefrontal cortex firing rate in anesthetized rats could not be blocked by [[D1 receptor|D<sub>1</sub>]] or [[alpha-2 blocker|α<sub>2</sub>-adrenergic receptor antagonist]]s, but could be potentiated by [[NMDA]] or an α<sub>1</sub>-adrenergic receptor antagonist, suggesting a glutamatergic mechanism.<ref>{{cite journal|last1=Di Miceli|first1=M|last2=Gronier|first2=B|title=Psychostimulants and atomoxetine alter the electrophysiological activity of prefrontal cortex neurons, interaction with catecholamine and glutamate NMDA receptors.|journal=Psychopharmacology|date=June 2015|volume=232|issue=12|pages=2191–205|doi=10.1007/s00213-014-3849-y|pmid=25572531}}</ref> In [[Laboratory rat|Sprague Dawley rats]], atomoxetine reduces [[GRIN2B|NR2B]] protein content without altering transcript levels.<ref name = PMID24348020>{{cite journal|last1=Udvardi|first1=PT|last2=Föhr|first2=KJ|last3=Henes|first3=C|last4=Liebau|first4=S|last5=Dreyhaupt|first5=J|last6=Boeckers|first6=TM|last7=Ludolph|first7=AG|title=Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.|journal=Drug design, development and therapy|date=2013|volume=7|pages=1433–46|doi=10.2147/DDDT.S50448|pmid=24348020}}</ref> Aberrant glutamate and NMDA receptor function have been implicated in the etiology of [[ADHD]].<ref>{{cite journal|last1=Maltezos|first1=S|last2=Horder|first2=J|last3=Coghlan|first3=S|last4=Skirrow|first4=C|last5=O'Gorman|first5=R|last6=Lavender|first6=TJ|last7=Mendez|first7=MA|last8=Mehta|first8=M|last9=Daly|first9=E|last10=Xenitidis|first10=K|last11=Paliokosta|first11=E|last12=Spain|first12=D|last13=Pitts|first13=M|last14=Asherson|first14=P|last15=Lythgoe|first15=DJ|last16=Barker|first16=GJ|last17=Murphy|first17=DG|title=Glutamate/glutamine and neuronal integrity in adults with ADHD: a proton MRS study.|journal=Translational psychiatry|date=18 March 2014|volume=4|pages=e373|doi=10.1038/tp.2014.11|pmid=24643164}}</ref><ref>{{cite journal|last1=Chang|first1=JP|last2=Lane|first2=HY|last3=Tsai|first3=GE|title=Attention deficit hyperactivity disorder and N-methyl-D-aspartate (NMDA) dysregulation.|journal=Current pharmaceutical design|date=2014|volume=20|issue=32|pages=5180–5|pmid=24410567}}</ref>

Atomoxetine also reversibly inhibits [[GIRK]] currents in [[Xenopus|''Xenopus'' oocytes]] in a concentration-dependent, voltage-independent, and time-independent manner.<ref name = PMID20393461>{{cite journal|last1=Kobayashi|first1=T|last2=Washiyama|first2=K|last3=Ikeda|first3=K|title=Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.|journal=Neuropsychopharmacology|date=June 2010|volume=35|issue=7|pages=1560–9|doi=10.1038/npp.2010.27|pmid=20393461}}</ref> K<sub>ir</sub>3.1/3.2 [[ion channel]]s are opened downstream of [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]], [[Alpha-2 adrenergic receptor|α<sub>2</sub>]], [[Dopamine receptor D2|D<sub>2</sub>]], and [[Adenosine A1 receptor|A<sub>1</sub>]] stimulation, as well as other [[Gi alpha subunit|G<sub>i</sub>]]-coupled receptors.<ref name = PMID20393461/> Therapeutic concentrations of atomoxetine are within range of interacting with GIRKs, especially in CYP2D6 poor metabolizers.<ref name = PMID20393461/> It is not known whether this contributes to the therapeutic effects of atomoxetine in ADHD.

4-Hydroxyatomoxetine, the major active metabolite of atomoxetine in CYP2D6 extensive metabolizers, has been found to have sub-micromolar affinity for [[opioid receptor]]s, acting as an antagonist at [[Mu opioid receptor|μ-opioid receptors]] and a partial agonist at [[Kappa opioid receptor|κ-opioid receptors]].<ref name="PMID15225731">{{cite journal|last=Creighton|first=CJ|author2=Ramabadran, K|author3= Ciccone, PE|author4= Liu, J|author5= Orsini, MJ|author6= Reitz, AB|title=Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect.|journal=Bioorganic & Medicinal Chemistry Letters|date=2 August 2004|volume=14|issue=15|pages=4083–5|pmid=15225731|doi=10.1016/j.bmcl.2004.05.018}}</ref> It is not known whether this contributes to the therapeutic effects of atomoxetine in ADHD.

===Pharmacokinetics===
Orally administered atomoxetine is rapidly and completely absorbed.<ref name = PMID15910008>{{cite journal|last1=Sauer|first1=JM|last2=Ring|first2=BJ|last3=Witcher|first3=JW|title=Clinical pharmacokinetics of atomoxetine.|journal=Clinical pharmacokinetics|date=2005|volume=44|issue=6|pages=571–90|doi=10.2165/00003088-200544060-00002|pmid=15910008}}</ref> Hepatic first-pass metabolism is dependent on [[CYP2D6]] activity, resulting in an [[bioavailability|absolute bioavailability]] of 63% for extensive metabolizers and 94% for poor metabolizers.<ref name = PMID15910008/> Maximum plasma concentration is reached in 1–2 hours.<ref name = PMID15910008/> If taken with food, the maximum plasma concentration decreases by 10-40% and delays the [[Pharmacokinetics|t<sub>max</sub>]] by 1 hour.<ref name = PMID15910008/> Drugs affecting gastric pH have no effect on oral bioavailability.<ref name = FDAPI />

Atomoxetine has a [[volume of distribution]] of 0.85 L/kg, with limited partitioning into red blood cells.<ref name = PMID15910008/> It is highly bound to plasma proteins (98.7%), mainly albumin, along with α<sub>1</sub>-acid glycoprotein (77%) and IgG (15%).<ref name = PMID15910008/><ref name = part2/> Its metabolite ''N''-desmethylatomoxetine is 99.1% bound to plasma proteins, while 4-hydroxyatomoxetine is only 66.6% bound.<ref name = PMID15910008/>

The half-life of atomoxetine varies widely between individuals, with an average range of 4.5 to 19 hours.<ref name = PMID15910008/><ref name = PMID26314574>{{cite journal|last1=Brown|first1=JT|last2=Bishop|first2=JR|title=Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.|journal=Pharmacogenomics|date=2015|volume=16|issue=13|pages=1513–20|doi=10.2217/PGS.15.93|pmid=26314574}}</ref> As atomoxetine is metabolized by CYP2D6, exposure may be increased 10-fold in CYP2D6 poor metabolizers.<ref name = PMID26314574/>

Atomoxetine, ''N''-desmethylatomoxetine, and 4-hydroxyatomoxetine produce minimal to no inhbition of [[CYP1A2]] and [[CYP2C9]], but inhibit [[CYP2D6]] in human liver microsomes at concentrations between 3.6-17 μmol/L.<ref name = PMID15910008/> Plasma concentrations of 4-hydroxyatomoxetine and ''N''-desmethylatomoxetine at steady state are 1.0% and 5% that of atomoxetine in CYP2D6 extensive metabolizers, and are 5% and 45% that of atomoxetine in CYP2D6 poor metabolizers.<ref name = FDAPI>{{cite web|title=Strattera Package Insert|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/pediatric/Atomoxetine.pdf|publisher=FDA}}</ref>

Atomoxetine is excreted unchanged in urine at <3% in both extensive and poor CYP2D6 metabolizers, with >96% and 80% of a total dose being excreted in urine, respectively.<ref name = PMID15910008/> The fractions excreted in urine as 4-hydroxyatomoxetine and its glucuronide account for 86% of a given dose in extensive metabolizers, but only 40% in poor metabolizers.<ref name = PMID15910008/> CYP2D6 poor metabolizers excrete greater amounts of minor metabolites, namely ''N''-desmethylatomoxetine and 2-hydroxymethylatomoxetine and their [[Drug metabolism|conjugates]].<ref name = PMID15910008/>

[[File:Atomoxetine metabolism.png|700px|thumb|center|Major metabolites of atomoxetine in humans.<ref name = PMID15910008/>]]

====Pharmacogenomics====
Chinese adults homozygous for the hypoactive CYP2D6*10 allele have been found to exhibit two-fold higher AUCs and 1.5-fold higher maximum plasma concentrations compared to extensive metabolizers.<ref name = PMID15910008/>

Japanese men homozygous for CYP2D6*10 have similarly been found to experience two-fold higher AUCs compared to extensive metabolizers.<ref name = PMID15910008/>

==Chemistry==
Atomoxetine, or (−)-methyl[(3''R'')-3-(2-methylphenoxy)-3-phenylpropyl]amine, is a white, granular powder that is highly soluble in water.

<gallery>
File:Strattera 60mg capsule back.jpg|Strattera 60-mg capsule back
File:Lilly Strattera 60mg Capsule.jpg|Strattera 60-mg capsule front with Lilly logo
</gallery>

===Synthesis===
[[File:Atomoxetine-synthesis.png|thumb|none|1000px|Original synthesis of atomoxetine, as patented by [[Eli Lilly and Company]]<ref>{{cite patent |country= US|number= 4018895 A|status= patent|title= Aryloxyphenylpropylamines in treating depression|pubdate= 1977-04-19|fdate= 1975-09-17|pridate= 1974-01-10|invent1= Bryan B. Molloy|invent2= Klaus K. Schmiegel|assign1= Eli Lilly And Company}}</ref><ref>{{cite patent |country= US|number= EP0052492 B1|status= patent|title= 3-aryloxy-3-phenylpropylamines|pubdate= 1984-02-29|fdate= 1981-11-13|pridate= 1980-11-14|invent1= Bennie Joe Foster|invent2= Edward Ralph Lavagnino|assign1= Eli Lilly And Company|url=}}</ref>]]

===Detection in biological fluids===
Atomoxetine may be quantitated in plasma, serum or whole blood in order to distinguish extensive versus poor metabolizers in those receiving the drug therapeutically, to confirm the diagnosis in potential poisoning victims or to assist in the forensic investigation in a case of fatal overdosage.<ref>{{cite book |first=Randall C. |last=Baselt |title=Disposition of Toxic Drugs and Chemicals in Man|edition=8th |publisher=Biomedical Publications |location=Foster City, CA |year=2008 |pages=118–20 |isbn=0-931890-08-X}}</ref>

==History==
Atomoxetine is manufactured, marketed, and sold in the [[United States]] as the [[hydrochloride]] salt (atomoxetine HCl) under the brand name Strattera by [[Eli Lilly and Company]], the original [[patent]]-filing company and current U.S. patent owner. Atomoxetine was initially intended to be [[drug development|developed]] as an antidepressant, but it was found to be insufficiently efficacious for treating depression. It was, however, found to be effective for ADHD and was approved by the FDA in 2002 for the treatment of ADHD. Its patent expired in May 2017.<ref name="orangeBook">{{cite web|url=http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021411&Product_No=002&table1=OB_Rx |title=Patent and Exclusivity Search Results |accessdate=26 April 2009 |work=Electronic Orange Book |publisher=US Food and Drug Administration}}</ref> On May 30, 2017 the FDA approved the generic production by four pharmaceutical companies.<ref>{{Cite web|url=FDA.org/news events/newsroom/press announcements/ucm561096.htm|title=|last=|first=|date=|website=|access-date=}}{{dead link|date=August 2017|bot=medic}}{{cbignore|bot=medic}}</ref> On 12 August 2010, Lilly lost a lawsuit that challenged its patent on Strattera, increasing the likelihood of an earlier entry of a generic into the US market.<ref>{{cite news |url=http://www.chicagotribune.com/business/sns-ap-us-eli-lilly-patent,0,7016147.story|title=Drugmaker Eli Lilly loses patent case over ADHD drug, lowers revenue outlook | work=Chicago Tribune}}</ref> On 1 September 2010, Sun Pharmaceuticals announced it would begin manufacturing a generic in the United States.<ref>{{cite news|url=http://www.ibtimes.com/articles/48022/20100901/sun-pharma-usfda-strattera-capsules-eli-lilly-atomoxetine-hydrochloride-attention-deficit-hyperactiv.htm# |title=Sun Pharma receives USFDA approval for generic Strattera capsules |work=International Business Times |deadurl=yes |archiveurl=https://web.archive.org/web/20110407100949/http://www.ibtimes.com/articles/48022/20100901/sun-pharma-usfda-strattera-capsules-eli-lilly-atomoxetine-hydrochloride-attention-deficit-hyperactiv.htm |archivedate=7 April 2011 |df=dmy }}</ref> In a 29 July 2011 conference call, however, Sun Pharmaceutical's Chairman stated "Lilly won that litigation on appeal so I think [generic Strattera]’s deferred."<ref>{{cite news|url=http://www.sunpharma.com/images/finance/FY12%20Q1%20Earnings%20Call%20Transcript.pdf |title=Sun Pharma Q1 2011-12 Earnings Call Transcript 10.00 am, July 29, 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20110929013747/http://www.sunpharma.com/images/finance/FY12%20Q1%20Earnings%20Call%20Transcript.pdf |archivedate=29 September 2011 |df=dmy }}</ref>

==Society and culture==

===Brand names===
In India, atomoxetine is sold under brand names including Attentrol [Sun Pharma], Axepta, [Intas Pharma] Attera [Icon pharma], Tomoxetin [Torrent Pharma], Atokem [Alkem Pharma], and Attentin [Ranbaxy Pharma].

In Romania, atomoxetine is sold under the brand name Strattera.

In Iran, atomoxetine is sold under brand names including stramox by TeKaJe Co.

==Research==
There has been some suggestion that atomoxetine might be a helpful adjunct in people with [[major depression]], particularly in cases with concomitant ADHD.<ref>{{cite journal |vauthors=Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J |lastauthoramp=yes |title=Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity |journal=The Journal of Clinical Psychiatry |volume=67|issue=3 |pages=415–20 |date=March 2006|pmid=16649828 |doi=10.4088/JCP.v67n0312}}</ref><ref>{{cite journal |vauthors=Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH |title=Augmentation with open-label atomoxetine for partial or non-response to antidepressants |journal=The Journal of Clinical Psychiatry|volume=66 |issue=10 |pages=1234–8 |date=October 2005 |pmid=16259536 |doi=10.4088/JCP.v66n1005}}</ref><ref>{{cite journal |vauthors=Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J |lastauthoramp=yes |title=Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms |journal=Journal of the American Academy of Child and Adolescent Psychiatry |volume=44|issue=9|pages=915–24 |date=September 2005 |pmid=16113620|doi=10.1097/01.chi.0000169012.81536.38}}</ref>

==See also==
* [[Fluoxetine]] (modified base and same termination of the molecule)
* [[Orphenadrine]] (modified base and similar termination of the molecule) it is a variant of the same structure

==References==
{{Reflist|30em}}

==External links==
* [http://www.rxlist.com/cgi/generic3/strattera.htm RxList.com – Strattera]
* [http://medlibrary.org/drugs/other/strattera.html Detailed Strattera Consumer Information: Uses, Precautions, Side Effects]
* [https://web.archive.org/web/20110724021918/http://www.clinicalstudyresults.org/search/?company_id=8&drug_name_id=79&r=1&submitted=1&page=1 All disclosed Lilly trials]
* [http://www.druglib.com/druginfo/strattera/abstracts/ Strattera Related Published Studies]

{{ADHD pharmacotherapies}}
{{Antidepressants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Glutamate receptor modulators}}
{{Ion channel modulators}}
{{Monoamine reuptake inhibitors}}
{{Opioid receptor modulators}}
}}

[[Category:Amines]]
[[Category:Eli Lilly and Company]]
[[Category:Kappa agonists]]
[[Category:NMDA receptor antagonists]]
[[Category:Nootropics]]
[[Category:Opioid antagonists]]
[[Category:Phenol ethers]]
[[Category:Potassium channel blockers]]
[[Category:Serotonin-norepinephrine reuptake inhibitors]]
[[Category:Treatment and management of attention deficit hyperactivity disorder]]